PARIS—France has canceled its order for Merck & Co.’s COVID-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer’s competing drug before the end of January, the health minister said on Wednesday.
France is the first country to publicly say it has canceled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalizations and deaths in its clinical trial of high-risk individuals by about 30 percent.
“The latest studies weren’t good,” Olivier Veran told BFM TV.
Merck did not immediately respond to Reuters’ request for comment.
There are hopes Merck and Pfizer’s experimental pills could be a game-changer in reducing the chances of dying or hospitalization for those most at risk of severe illness.
France had placed an early order for 50,000 doses of the nucleoside analogue drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.
The cancellation would not incur a cost, Veran said.
In Italy, the office of the special commissioner for the COVID-19 emergency said on Nov. 18 it had received a mandate from the health ministry to buy 50,000 courses of Merck’s pill and another 50,000 of Pfizer’s. “The contract has not yet been finalized, but is in progress,” a spokesperson for the commissioner told Reuters on Tuesday.
Italian drug regulator Aifa’s head Nicola Magrini told a Senate committee on Dec. 9 the two treatments could be available in Italy from the end of January.
However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.
“There must and will be an evaluation, independently of the assessments of regulatory bodies,” Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.
Germany has already bought Merck’s antiviral treatment, health minister Karl Lauterbach told Reuters on Wednesday.
“This is a binding order,” he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.
The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.
Pfizer’s Paxlovid, a protease inhibitor, has shown near 90 percent efficacy in preventing COVID-19 hospitalizations and deaths in high-risk patients.
France had purchased that drug instead, Veran said, without saying how many doses it had secured.
“France is lined up to get it before the end of January,” Veran continued. It has not yet been decided whether the drug would be available over the counter in pharmacies, the minister said.
